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Background: Patients undergoing elective AAA-surgery identified by clinical risk factors and
dobutamine stress echocardiography (DSE) as being at high-risk often have considerable
cardiac complication rate despite the use of beta-blockers.
Methods: We studied 570 patients (mean age 69 9 years, 486 males) who underwent AAA-
surgery between 1991 and 2001 at the Erasmus MC. Patients were evaluated for clinical risk
factors (age>70 years, histories of MI, angina, diabetes mellitus, stroke, renal failure, heart
failure and pulmonary disease), DSE, statin and beta-blocker use. The main outcome was
a composite of perioperative mortality and MI within 30 days of surgery.
Results: Perioperative mortality or MI occurred in 51 (8.9%) patients. The incidence of the
composite endpoint was significantly lower in statin users compared to nonusers (3.7% vs.esented in an abstract format during the American Heart Association Scientific Sessions, November
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Statins, Beta-blockers and Aortic Aneurysm Surgery S9711.0%; crude odds ratio (OR): 0.31, 95% confidence interval (CI): 0.13-0.74; p Z 0.01). After
correcting for other covariates, the association between statin use and reduced incidence of
the composite endpoint remained unchanged (OR: 0.24,95% CI: 0.10-0.70; p Z 0.01). Beta-
blocker use was also associated with a significant reduction in the composite endpoint (OR:
0.24, 95% CI: 0.11-0.54). Patients using a combination of statins and beta-blockers appeared
to be at lower risk for the composite endpoint across multiple cardiac risk strata; particularly
patients with 3 or more risk factors experienced significantly lower perioperative events.
Conclusions: A combination of statin and beta-blocker use in patients with AAA-surgery is asso-
ciated with a reduced incidence of perioperative mortality and nonfatal MI particularly in
patients at the highest risk.
ª 2011 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Introduction
Despite recent advances in perioperative care the 30-day
mortality of elective abdominal aortic aneurysm (AAA)
surgery still varies between 2.7 and 5.5% in selected series,
up to 9% in population based studies.1,2 In fact, cardiac
related morbidity and mortality are one of the most
frequently observed perioperative complications.3,4 Thirty-
six percent of patients undergoing AAA-surgery have severe
coronary artery disease (CAD), whereas only 6% have normal
coronary arteries.5,6 Clinical risk assessment tools7e9 have
been used to risk stratify patients, and thereby identifying
those at particular benefit from beta- blockers.10,11 In two
separate studies perioperative beta-blocker use was shown
to be associated with a significant reduction in cardiac
death and nonfatal myocardial infarction.10,11 However, all
patients are not equally protected by beta-blocker
therapy.12 Patients identified by clinical risk factors and
dobutamine stress echocardiography (DSE) as being at high-
risk often have a considerable cardiac complication rate
despite the use of beta-blockers.12 Thus, additional treat-
ment options are necessary to improve perioperative
prognosis in high-risk patients undergoing major vascular
surgery. In that respect, we have previously shown that
patients who underwent major vascular surgery and were
statin users had a reduced risk of perioperative mortality as
compared to nonusers.13 However, in this case-control
study, we did not adjust for important predictors of peri-
operative mortality such as chronic pulmonary disease,14
DSE results, and a mix of acute and elective vascular
surgery patients were studied. Recently, Kertai et al.
showed that patients who survived AAA-surgery and were
statin users had a significantly lower incidence of long-term
all-cause and cardiovascular mortality compared with non-
statin users.15 The current study builds on the same group of
patients examining their perioperative course in relation to
clinical risk factors, DSE results, a combination of statin and
beta-blocker use and the incidence of perioperative
mortality and nonfatal myocardial infarction.
Methods
Patients and study design
The Erasmus Medical Center (MC) is an academic hospital in
Rotterdam, the Netherlands, which acts as a tertiaryreferral center for approximately 30 affiliated hospitals.
Between January 1991 and December 2001, a total of
75,581 patients over 18 years of age underwent 108,613
noncardiac surgical procedures at the Erasmus MC. Each
surgical technique performed was classified by treating
physicians according to a standardized national coding
system that was developed in cooperation with the
National Health Service and medical insurance companies.
The type of surgery, demographic data, medical history,
and information on the perioperative course of each
patient was then systematically uploaded to an electronic
database maintained by the Medical Information Depart-
ment; via this database 570 patients were identified who
underwent elective open infrarenal abdominal aortic
surgery.
Data collection and definition of risk factors
Along with clinical information, we also reviewed medical
files and discharge letters for additional information on
clinical risk factors, chronic cardiac medication use, intra-
operative and perioperative hospital course, and cause and
type of perioperative complications. Potential clinical
determinants of perioperative mortality and MI were
advanced age (> 70 years), gender, current stable or prior
angina pectoris, prior MI on the basis of medical history or
a finding of pathologic Q waves on the electrocardiography,
compensated congestive heart failure or a history of heart
failure, renal dysfunction (serum creatinine > 2mg/dl
(180 mmol/l)), current oral or insulin treatment for diabetes
mellitus, a history of prior cerebro-vascular accident
including transient ischemic attack, hypertension, chronic
pulmonary disease (forced expiratory volume in 1 s < 75% of
normal adjusted for age and gender) and smoking.14,16,17
The average of two fasting levels of total cholesterol, LDL
and HDL cholesterol levels were also included if they were
measured 3 months prior to abdominal aortic surgery.
Patients were defined as having elevated cholesterol levels
if total serum cholesterol level exceeded 212.7 mg/dl
(5.5 mmol/l) or the LDL cholesterol level was higher than
135.3 mg/dl (3.5 mmol/l). In addition, data from the
preoperative DSE were also collected if available. DSE was
performed as previously described,11 and a positive test
result for DSE was considered if new wall-motion abnor-
malities occurred. In addition, the year of operation was
also included given the influence of advances in perioper-
ative care and surgical techniques.
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According to routine procedure at Erasmus MC, patients
visited the outpatient clinic at least three months prior to
the planned major vascular surgery, and all patients were
also screened for medication use in conjunction their
medical history. During the study period additional cardiac
medications including beta-blockers or statins were
prescribed at the discretion of the attending physicians.
Patients continued taking their cardiac medication also on
the day of surgery, and oral medication use was resumed on
day 1 after surgery. Based on institutional guidelines aspirin
use was discontinued at least 10 days before elective AAA-
surgery. Two investigators (JK, DP), blinded to the patients’
perioperative outcome, reviewed medical records for
medication use including aspirin, ACE-inhibitor, beta-
blocker and statin use. Chronic medication use was ascer-
tained if medication use was documented at least one to
three months prior to hospital admission for surgery.
Definition of perioperative events
As part of the routine postoperative management all patients
were screened for cardiac enzyme elevations (creatine-
kinase (CK), creatine-kinase MB (CK-MB), cardiac troponin T),
and 12-lead electrocardiogram was made after major
vascular surgery (day 2, 3 and 7 or discharge). Perioperative
eventswere defined as a composite of all-causemortality and
MI occurring before discharge or within 30 days after surgery,
whichever came first. The cause of perioperative death was
retrieved from hospital records or autopsy results. MI was
diagnosed according to our institutional laboratory protocol
as a serumCK level ofmore than 190 U/l, and a CK-MB activity
above 24 IU/l, or the CK-MB activity fraction exceeding 6% of
total CK, or from 1996 as cardiac troponin T>0.1 ng/ml, and
by new Q waves > 1 mm or >30 ms.
Statistical analysis
Continuous variables were described as mean value  SD,
and categorical variables as percent frequencies. Differ-
ences between patient subgroups were evaluated by using
the t-test or chi-square test, as appropriate. The number of
perioperative events in the study was relatively limited.
Therefore, to avoid overfitting and to enable assessment of
the relation between clinical risk factors and the composite
of all-cause mortality and nonfatal MI, we used the revised
cardiac risk index developed by Lee et al.9 Since the deci-
sion to prescribe statin or beta-blocker therapy was not
randomized, adjustments were made for baseline charac-
teristics that may have influenced the decision to use either
medication. Separate propensity scores were constructed
using multiple logistic regression analyses. Baseline clinical
characteristics that had an independent association with the
decision to prescribe statins or beta-blockers (P Z 0.25)
were included in the multivariable propensity score. Uni-
variable logistic regression analyses were performed to
study the relation between statin, beta-blockers, baseline
clinical characteristics and the composite endpoint.
Multivariable logistic regression analysis was also per-
formed to study the association of statins and beta-blockers with the composite endpoint, with adjustments
for baseline clinical characteristics and the two propensity
scores. The discriminatory power of the multivariable
regression model was quantified by the c-index, which is
identical to the area under the receiver operating charac-
teristic curve; the c-index ranges from 0.5 (not predictive
at all) to 1.0 (optimal performance). The performance of
the multivariate regression model was further assessed
with Hosmer-Lemeshow goodness-of-fit test.18 Finally, to
reveal a possible heterogeneity between statin or beta-
blocker use and baseline clinical characteristics interac-
tion terms were included in the models. Odds ratios (ORs)
and corresponding 95% confidence intervals (CIs) are
reported. All analyses were performed using SPSS statistical
software (SPSS Inc., Chicago, Illinois, version 11.0).
Results
Patient characteristics
Patient characteristics according to statin use are described
in Table 1. Statin usersweremore often younger,women, and
had a higher body mass index than nonusers. Furthermore,
statin users had a higher prevalence of cardiovascular
disease; a higher prevalence of renal dysfunction,more often
underwent prior coronary revascularization, and had a lower
prevalence of chronic pulmonary disease. There were no
significant differences in total cholesterol, LDL- and HDL-
cholesterol levels between statin users compared to non-
users. Statin usersmore frequently used concomitant cardiac
medications compared to statin nonusers. Of the 570
patients, 340 also underwentDSEone to threemonthsprior to
surgery. Patients who were statin users more often had
a positive DSE compared to nonusers. In 162 patients who
were statin users themost frequently prescribed statins were
simvastatin (71.6%), atorvastatin (14.8%), pravastatin (8.6%),
cerivastatin (3.7%) and fluvastatin (1.2%), respectively. Peri-
operative mortality or MI occurred in 51 (8.9%) patients.
Among these, there were 24 (47%) cardiovascular complica-
tions: 18 cardiac deaths, four nonfatal MIs and stroke in two
patients. The most common non-vascular causes of death
were septic complications in 10, respiratory insufficiency in
nine and intestinal necrosis in eight patients. Autopsy was
performed in 28 (55%) patients. In patients who died and
underwent postmortem examination the cause of death was
more often classified as cardiac death (50%) than in patients
who died but did not undergo autopsy (21%).
Univariable analyses
A history of chronic pulmonary disease was the most
important determinant of the composite endpoint
(Table 2). Patients with a history of chronic pulmonary
disease had an almost 5-fold increased risk of perioperative
adverse events compared to patients without such history.
Other significant univariable predictors of the composite
endpoint were prior cerebrovascular accident, renal
dysfunction, advanced age (>70 years) and previous MI. A
positive DSE result was also a significant univariable
predictor of perioperative events. Patients with a new wall-
motion abnormality during DSE had a significantly higher
Table 1 Characteristics of the population.
Characteristics Patients who used statinsa,
N Z 162 (%)
Patients who did not use statins,
N Z 408 (%)
P-valueb
Demographics
Age, years 65.1  8.9 70.5  8.6 <0.001
Age > 70 years 61 (38) 258 (63) <0.001
Male sex 126 (78) 360 (88) 0.002
Clinical variables
Body mass index (kg/m2) 25.8  3.5 24.7  2.8 0.002
Current smoker 49 (30) 130 (32) 0.7
Blood pressure (mmHg)
Systolic 146.7  20.3 146.2  19.6 0.8
Diastolic 85.2  10.4 86.0  11.0 0.5
Cholesterol (mmol/l (mg/dl))
Total 5.6  1.2 (216  46.4) 5.7  1.1 (220.4  42.5) 0.9
LDL 3.8  1.1 (146.9  42.5) 3.8  0.6 (146.9  23.2) 0.8
HDL 1.1  0.5 (42.5  19.3) 1.1  0.3 (42.5  11.6) 0.8
Medical history
Current or stable angina pectoris 47 (29) 67 (16) 0.001
Previous myocardial infarction 61 (38) 78 (19) <0.001
Congestive heart failure 8(5) 11 (3) 0.2
Diabetes mellitus 14 (9) 22 (5) 0.2
Prior cerebrovascular accident 21 (13) 64 (16) 0.4
Renal insufficiency 16 (10) 15 (4) 0.007
Pulmonary disease 27 (17) 124 (30) 0.001
Hypertension 77 (47) 200 (49) 0.8
Prior coronary revascularizationc 24 (15) 23 (6) 0.001
Chronic cardiac medication
ACE inhibitors 69 (43) 113 (28) 0.001
Aspirin 57 (35) 72 (18) <0.001
Beta-blockers 103 (64) 153 (38) <0.001
Dobutamine stress echocardiography 0.03
New wall motion abnormalities 32 (20) 49 (12)
No new wall motion abnormalities 75 (46) 184 (45)
No test performed 55 (34) 175 (43)
a All data are presented as number (percentage) unless otherwise indicated; LDL, low-density lipoprotein; HDL, high-density lipo-
protein. For definition of risk factors see Methods.
b Chi-square test or independent t-test.
c It is a combination of prior coronary bypass graft surgery and percutaneous transluminal coronary angioplasty (only one procedure
performed in each group).
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without stress induced myocardial ischemia (17.3% vs. 7.3%;
P < 0.001). Although there was a positive trend for
improved perioperative outcome in patients who under-
went previous coronary revascularization this association
was not statistically significant (Table 2). There was no
significant association between the year of operation and
the composite endpoint (crude OR, 1.0, 95% CI, 0.9e1.1). In
further univariable analyses, patients using statins or beta-
blockers were at a significantly lower risk of perio-perative
adverse events compared to patients not using either of
these medications. Compared with nonusers, patients who
were using statins had a threefold reduced risk- and
patients using beta-blockers had a two-fold lower risk of
the composite endpoint. There was a trend for aspirin and
ACE inhibitors to reduce the incidence of perioperative
events, however, this association was not statistically
significant.Propensity to prescribe statins or beta-blockers
The propensity score for statin use showed that patients
were more likely to be prescribed statins if they were
younger, had a history of CAD or renal dysfunction, or had
elevated total cholesterol levels (Table 3). The propensity
score for beta-blocker use showed that beta-blockers were
more often used if patients were younger, or had a history
of CAD, but were used less often in those with chronic
pulmonary disease (Table 3).Effect of statin use according to the revised
cardiac risk index
Among the 246 patients with a risk score of one, there was
one perioperative event observed in the 17.5% of patients
using statins and four events (2%) in the remaining 203
Table 2 Univariable relation between clinical characteristics and perioperative mortality or myocardial infarction (NZ 570).
Variablesa No. of
patients
Perioperative
mortality or myocardial
infarction, no. (%)
Odds ratio
(95% confidence interval)
X2 test P-value
Demographics
Age, years
>70 319 38 (11.9) 2.5 (1.3e4.7) 7.4 0.007
<70 251 13 (5.2) 1
Gender
Men 486 42 (8.6) 0.78 (0.36e1.68) 0.4 0.5
Women 84 9 (10.7) 1
Medical history
Current or stable angina pectoris
Yes 114 14 (12.3) 1.6 (0.8e3.0) 8.1 0.2
No 456 37 (8.1) 1
Previous myocardial infarction
Yes 139 20 (14.4) 2.2 (1.2e3.9) 6.4 0.01
No 431 31 (7.2) 1
Congestive heart failure
Yes 19 4 (21.1) 2.9 (0.9e9.0) 3.3 0.07
No 551 47 (8.5) 1
Diabetes mellitus
Yes 36 6 (16.7) 2.2 (0.9e5.5) 2.7 0.1
No 534 45 (8.4) 1
Prior cerebrovascular accident
Yes 85 20 (23.5) 4.5 (2.4e8.4) 22.7 <0.001
No 485 31 (6.4) 1
Renal insufficiency
Yes 31 8 (25.8) 4.0 (1.7e9.5) 10.0 0.002
No 539 43 (7.9) 1
Pulmonary disease
Yes 151 30 (19.8) 4.7 (2.6e8.5) 26.1 <0.001
No 419 21 (5.0) 1
Prior coronary revascularizationb
Yes 47 3 (6.4) 0.7 (0.2e2.3) 0.4 0.5
No 523 47 (9.0) 1
Dobutamine stress echocardiography
New wall motion abnormalities 81 14 (17.3) 2.5 (1.2e5.2) 5.5 0.02
No new wall motion abnormalities 259 19 (7.3) 0.9 (0.5e1.8) 0.04 0.8
No dobutamine stress echocardiography 230 18 (7.8) 1
Chronic cardiac medication
Statins
Yes 162 6 (3.7) 0.31 (0.13e0.74) 7.0 0.01
No 408 45 (11.0) 1
Beta-blockers
Yes 256 15 (5.8) 0.48 (0.26e0.90) 5.2 0.02
No 314 36 (11.4) 1
Chronic cardiac medication
Aspirin
Yes 129 9 (6.9) 0.73 (0.34e1.55) 0.7 0.4
No 431 40 (9.2) 1
ACE inhibitors
Yes 182 15 (8.2) 0.88 (0.47e1.67) 0.1 0.7
No 380 35 (9.2) 1
a For definition of risk factors see Methods.
b It is a combination of prior coronary bypass graft surgery and percutaneous transluminal coronary angioplasty (only one procedure
performed in each group).
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Table 3 Odds ratios for propensity scores associated with prescription of statin or b-blocker use.
Characteristicsa Statin use b-Blocker use
Regression
coefficient
Odds
ratio (95% CI)
P-value Regression
coefficient
Odds
ratio (95% CI)
P-value
Age 0.07 0.93 (0.91e0.96) <0.001 0.07 0.98 (0.96e1.01) 0.1
Male sex 0.79 0.45 (0.26e0.78) 0.005 0.40 0.67 (0.41e1.11) 0.12
Current stable or history of angina pectoris 0.91 2.50 (1.52e4.10) <0.001 0.99 2.70 (1.73e4.22) <0.001
Previous myocardial infarction 1.14 3.12 (1.96e4.96) <0.001 1.16 3.18 (2.09e4.83) <0.001
Congestive heart failure 0.08 1.08 (0.35e3.38) 0.88 0.23 1.25 (0.46e3.46) 0.66
Diabetes mellitus 0.62 1.86 (0.86e3.90) 0.11 . . .
Prior cerebrovascular accident . . . 0.52 1.68 (1.03e2.76) 0.04
Renal dysfunction 1.03 2.80 (1.25e6.24) 0.01 0.54 1.73 (0.80e3.77) 0.17
Chronic pulmonary disease 0.78 0.46 (0.27e0.78) 0.004 0.49 0.61 (0.41e0.96) 0.02
Elevated total cholesterol 1.14 3.12 (2.04e4.78) <0.001 . . .
a Characteristics that had an independent relationship with the decision to prescribe statins or b-blockers at p Z 0.25, and were
included the multivariable logistic regression model to form the propensity score; CI, confidence interval. Ellipses indicate variables that
did not reach a p Z 025 level to be included in the multivariable logistic regression models.
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two, 36% were using statins. One perioperative event (1.1%)
occurred in this group, whereas 24 (15.5%) events were
observed in patients not using statins (p < 0.001). Finally, in
the 82 patients with a risk score of 3 or more, 39% were
statin users, and of those 12.5% had perioperative mortality
or MI, while the event rate was 34% in those not using
statins (p Z 0.02).
Additional beneficial effect of statin use according
to beta-blocker use
Among 103 patients receiving a combination of beta-
blockers and statins only two (1.9%) perioperative events
occurred compared to 13 (8.5%) perioperative events in 153
patients using only beta-blockers (OR, 0.21, 95% CI, 0.05-
0.96). In the 314 patients who were beta-blocker nonusers,
18.7% were using statins. Four (6.8%) perioperative events
occurred in this group, whereas approximately 50% more
events occurred in patients who were nonusers (OR, 0.51,
95% CI, 0.17-1.50). Test for heterogeneity revealed noTable 4 Multivariable relation between clinical characteristics
myocardial infarction.
Variables Odds ratios (95%
interval)
Age > 70 years 3.0 (1.23e7.30)
Chronic pulmonary disease 5.57 (2.60e12.0)
Revised cardiac risk indexa one
point increase
3.52 (2.10e6.03)
Beta-blocker use 0.24 (0.11e0.54)
Propensity score for beta-
blocker use
3.51 (0.13e92.78
Statin use 0.24 (0.10e0.70)
Propensity score for statin use 5.17 (0.34e79.10
a To compose the revised cardiac risk index 1 point is assigned to eac
ischemic heart disease (history of myocardial infarction, positive d
history of heart failure, history of cerebrovascular disease, diabetesevidence for a differential effect of statin use in these
patient categories (P-value for interaction Z 0.36).
Multivariable analyses
Patients with advanced age (>70 years) and with a history of
pulmonary disease remained at an elevated risk for peri-
operative mortality and nonfatal MI after an adjustment for
the revised cardiac risk index (Table 4). One point increase in
the revised cardiac risk index was also significantly associ-
ated with adverse perioperative outcomes. Finally, the
association between statins, beta-blockers and the
composite endpoint remained statistically significant. Both,
statin and beta-blocker use were associated with 4-fold
reduction in perioperative mortality and nonfatal myocar-
dial infarction. In a separate model, a trend for aspirin and
ACE-inhibitors to reduce the likelihood for perioperative
mortality and MI was revealed but these associations were
not statistically significant. The combination of the revised
cardiac risk index, statin and beta-blocker use with
the corresponding propensity scores had excellent, statin and beta-blocker use and perioperative mortality or
confidence X2 test P-value
5.8 0.02
19.3 <0.001
21.1 <0.001
11.7 0.001
) 0.6 0.5
6.8 0.01
) 1.4 0.2
h of the following characteristics: high-risk type of surgery, known
obutamine stress echocardiography, history of angina pectoris),
mellitus, and preoperative serum creatinine level >2.0 mg/dl.
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goodness-of-fit Hosmer-Lemeshow test; X2Z 2.9, pZ 0.93).
Combined effect of statins and beta-blockers
according to the revised cardiac risk index
Based on the number of clinical risk scores, a combination
of statin and beta-blocker use the incidence of the
composite endpoint was calculated (Fig. 1). Patients with
a risk score of 1 had a low event rate, with those receiving
combined therapy tending to experience the lowest
event rates (pZ ns). Although not statistically significant,
a similar relationship was observed in patients with a risk
score of 2. However, in patients at highest risk (risk score
of 3 or more) a significant descending gradation of risk was
revealed with those on combined therapy experiencing
only 7.7% perioperative event rates.
Discussion
The current study showed that clinical risk factors and DSE
data aggregated in the revised cardiac risk index were
significant predictors of perioperative mortality and
nonfatal MI. In addition patients who were statin users had
a four-fold reduced risk of perioperative events. Although,
statin users had a different clinical risk profile than non-
users, this association remained after adjustment for these
differences. Furthermore, our findings also suggest the
benefit of combined therapy with statins and beta-blockers
especially in patients at the highest risk as defined by the
revised cardiac risk index.
Clinical predictors of adverse perioperative outcome for
patients with abdominal aortic surgery have been well docu-
mentedandclearly identify ahistoryof CAD, renal dysfunction
and pulmonary comorbidity as having prognostic significance
in these patients.14,16,17 Among patients in whompostmortem 
 
 
Figure 1 Incidence of perioperative mortality and myocardial inf
by the revised cardiac risk index (ischemic heart disease, history o
insulin therapy for diabetes, preoperative serum creatinine >2 mgexamination was performed in the present study, the cause of
deathwasmoreoftenclassifiedas cardiac than inpatientswho
died but did not undergo autopsy (50% vs. 21%). This suggests
that the incidence and impact of cardiac complications after
abdominal aortic surgery could be underestimated in clinical
practice. There is growing evidence, which points to an asso-
ciation between the presence of an AAA, and atheroscle-
rosis,19,20whichmaywell explain theobservedhighproportion
of adverse events due to cardiovascular causes. While favor-
able actions of statins on atherosclerosis and vascular
properties have mainly been attributed to cholesterol low-
ering,21e27 statins may also attenuate coronary artery plaque
inflammation, influence plaque stability in addition to
antithrombogenic, antiproliferative and leukocyte-adhesion
inhibiting effects.21e23,28 All these properties of statins may
stabilize unstable coronary plaques, and thereby reducing
myocardial ischemia and subsequent myocardial damage.
Consistent with previous studies, an association between
beta-blocker use and reduced perioperative events was
observed.10,11 Statin use appears to be independently
associated with a reduced incidence of perioperative
mortality and MI even in the presence of beta-blockers.
Beta-blockers apart form their direct hemodynamic effect
such as reduction in heart rate and contractility may also
indirectly influence the determinants of shear stress and
reduce inflammation through decreases in sympathetic
tone.29 These properties of beta-blockers may reinforce the
effect of statins on vulnerable plaques.
To date, there are few studies that have evaluated the
effect of statin use on the reduction of perioperative and
long-term cardiovascular complications in patients under-
going vascular surgery.15,30e32 The findings of Lindenauer
et al.30 showed in a large group of patients that treatment
with statins was associated with a significant reduction of
in-hospital mortality across different risk and surgical
categories in patient undergoing major noncardiac surgery.
In a clinical trial of Durazzo et al., a marked reduction ofarction. Results are based on the number of clinical risk factors
f congestive heart failure, history of cerebrovascular disease,
/dl), statin and beta-blocker use.
Statins, Beta-blockers and Aortic Aneurysm Surgery S103adverse cardiovascular events among vascular surgery
patients who were randomly assigned to atorvastatin
compared with placebo was reported.31 The study showed
that short-term (within 6 months) treatment with atorvas-
tatin significantly reduced the incidence of cardiovascular
events after vascular surgery (atorvastatin vs. placebo,
8.3% vs. 26.0%). Landesberg et al.32 also found that patients
who underwent major vascular surgery and were using
lipid-lowering therapy had a tendency for better event-free
survival rates. Kertai et al. showed that statin therapy was
associated with a lower all-cause and cardiovascular
mortality during follow-up after AAA surgery.15
In our previous case-control study, we found that statin
users had a four-fold reduction of in-hospital mortality as
compared to nonusers.13 The current study builds upon
these earlier findings by highlighting the combined benefi-
cial effect of statin and beta-blocker use for the reduction
of perioperative mortality and nonfatal MI in a large cohort
of patients undergoing elective AAA-surgery. Secondly, the
revised cardiac risk index was also applied to adjust for
important clinical risk factors and DSE test results. Finally,
we used propensity scores and multivariable modeling to
adjust for potential confounders. Beta-blockers may offer
protection in patients at low- to intermediate risk but their
effect appears to be marginal in patients at the highest
risk.12 In this context, statins appear to have additional
beneficial effect for the prevention of perioperative
mortality and nonfatal MI.
This study has certain limitations, which should be
considered when interpreting the results. Statin users had
a higher incidence of CAD and renal dysfunction, and as
a result of that, were more often prescribed other cardiac
medications or underwent previous coronary revasculari-
zation prior to the elective AAA-surgery. It is possible,
therefore, that statin users would have also been more
likely to receive better medical attention during the peri-
operative period. Moreover, the incidence of perioperative
mortality was relatively higher than reported from other
studies (2.7-5.5%).14 This may question the generalizability
of our findings. However, it is important to note that
patients in this study were operated in a tertiary referral
center, and studies that reported lower mortality rates
usually implied strict inclusion criteria and selected
patients at low risk for perioperative complications.14
Finally, given the retrospective nature of our study it was
not possible to ascertain unless it was clearly stated in the
medical records whether treatment with statins was dis-
continued throughout the perioperative period or dis-
continued during hospitalization. This could be particularly
relevant since current American Heart Association Clinical
Advisory Statement on statin safety suggests the discon-
tinuation of statin treatment during major surgery or crit-
ical illness.33 Conversely a recent study has suggested that
discontinuation of statins may be associated with adverse
outcomes in hospitalized patients.34Conclusions
This study revealed that a combination of statin and beta-
blocker use in patients undergoing AAA-surgery is associ-
ated with a reduced incidence of perioperative mortalityand nonfatal MI, particularly in patients at the highest risk
for perioperative complications. This early evidence of the
beneficial effect of statin use particularly in combination
with beta-blocker use should be confirmed in future large-
scale clinical trials.References
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